Bevacizumab, a humanized antibody to VEGF, received accelerated US Food and Drug Administration (FDA) approval in May 2009 for use as a single agent in patients with GBM who have progressive disease following front-line therapy consisting of surgical resection, radiotherapy, and temozolomide[4, 13, 14]. The gene discussed is VEGFA; the disease is glioblastoma.